NCT05215262

Brief Summary

This study will consist of a randomized controlled trial of a motivational interviewing intervention for adolescents with diagnosed sexually transmitted infections (STIs). The sessions will provide HIV/STI prevention education, use motivational interviewing (MI) to enhance goal setting, and providing skill building and referral to evidence based STI and HIV prevention strategies Pre-Exposure Prophylaxis (PrEP), condom use, and partner notification.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
94

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2022

Typical duration for not_applicable

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 18, 2022

Completed
13 days until next milestone

First Posted

Study publicly available on registry

January 31, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

March 8, 2022

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 5, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 5, 2024

Completed
12 months until next milestone

Results Posted

Study results publicly available

May 22, 2025

Completed
Last Updated

May 22, 2025

Status Verified

May 1, 2025

Enrollment Period

2.2 years

First QC Date

January 18, 2022

Results QC Date

April 14, 2025

Last Update Submit

May 21, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Prevention Self-efficacy

    Differences in the change in prevention self-efficacy scores from baseline to three months between the control arm compared to the intervention arm will be assessed using a modified version of the Generalized Self Efficacy (GSE) measure. The GSE measure is a 10-item measure assessing participants' confidence in carrying out their self-identified prevention goals. The total score of the GSE measure is calculated by finding the sum of all 10 items - the sum ranging between 10 and 40 with a higher score indicating more self-efficacy. This outcome is measuring the differences in mean total scores over time.

    Baseline and 3 months

Secondary Outcomes (4)

  • Recruitment Feasibility

    Baseline

  • Intervention Acceptability

    1 week

  • Intervention Acceptability

    3 months

  • Retention Feasibility

    3 months

Study Arms (2)

T.A.K.E. Steps Motivational Interviewing Intervention

EXPERIMENTAL

Four MI intervention sessions, 1:1 with participant and health coach.

Behavioral: Treat Act Know Engage (T.A.K.E.) Steps

Standard of Care

ACTIVE COMPARATOR

Standard of Care control visit with primary care physician (PCP)

Behavioral: Standard or Care

Interventions

Intervention sessions will consist of psychoeducation, HIV/STI goal identification, referral to HIV testing and PrEP, and communication skill building.

T.A.K.E. Steps Motivational Interviewing Intervention

S.O.C. arm will receive treatment as usual. After the baseline interview, participants will be referred to their PCP for management of any clinical issues that arise. Their clinic visit schedule will follow their clinical needs and recommendations of their clinic provider

Standard of Care

Eligibility Criteria

Age13 Years - 19 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Males or females aged 13 to 19 years.
  • History of ≥1 STI in the 30 days prior to recruitment
  • Confirmed treatment for a laboratory confirmed diagnosis of Trichomonas vaginalis (via microscopy or nucleic acid amplification test \[NAAT\]), Neisseria gonorrhea (NAAT), Chlamydia trachomatis (NAAT), Treponema pallidum \[via new positive rapid plasmin reagin (RPR) assay\] within the prior 30 days
  • Self-reported HIV negative status.
  • Able to speak and understand written English

You may not qualify if:

  • Unable to provide informed consent due to intoxication or severe psychological distress.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Primary Care, CHOP Clinic 3550 Market St

Philadelphia, Pennsylvania, 19104, United States

Location

CHOP Primary Care, Roxborough

Philadelphia, Pennsylvania, 19128, United States

Location

CHOP Karabots Pediatric Care Center, West Philadelphia

Philadelphia, Pennsylvania, 19139, United States

Location

CHOP Primary Care, Cobbs Creek

Philadelphia, Pennsylvania, 19139, United States

Location

CHOP Primary Care, South Philadelphia

Philadelphia, Pennsylvania, 19145, United States

Location

MeSH Terms

Interventions

Standard of Care

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Results Point of Contact

Title
Sarah Wood, MD, MSHP
Organization
Mount Sinai Adolescent Health Center

Study Officials

  • Sarah M Wood, MD, MSHP

    Children's Hospital of Philadelphia

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 18, 2022

First Posted

January 31, 2022

Study Start

March 8, 2022

Primary Completion

June 5, 2024

Study Completion

June 5, 2024

Last Updated

May 22, 2025

Results First Posted

May 22, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations